For citations:
Rudakova A.V., Ugrekhelidze D.T., Krylov V.A. Economic consequences of mandatory price re-registration for medicines from the high-cost nosology program. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(3):27-33. (In Russ.) https://doi.org/10.37489/2588-0519-2020-3-27-33
Email this article 